HRP20231281T1 - Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom - Google Patents
Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom Download PDFInfo
- Publication number
- HRP20231281T1 HRP20231281T1 HRP20231281TT HRP20231281T HRP20231281T1 HR P20231281 T1 HRP20231281 T1 HR P20231281T1 HR P20231281T T HRP20231281T T HR P20231281TT HR P20231281 T HRP20231281 T HR P20231281T HR P20231281 T1 HRP20231281 T1 HR P20231281T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- seq
- antigen
- acid sequence
- bispecific antibody
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 25
- 239000000427 antigen Substances 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 239000012634 fragment Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 102000055862 human MUC16 Human genes 0.000 claims 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Claims (14)
1. Bispecifično antitijelo ili njegov fragment za vezanje antigena koji sadrži prvu antigen-vežuću domenu koja specifično veže humani CD3, i drugu antigen vežuću domenu koja specifično veže humani MUC16, pri čemu druga antigen-vežuća domena sadrži domene HCDRI-HCDR2-HCDR3-LCDRI-LCDR2-LCDR3, tim redom, koje sadrže aminokiselinske nizove SEQ ID NOs: 20-22-24-28-30-32.
2. Bispecifično antitijelo ili fragment za vezanje antigena prema zahtjevu 1, koji sadrži varijabilnu regiju teškog lanca koja sadrži aminokiselinski niz SEQ ID NO: 18, i varijabilnu regiju lakog lanca koja sadrži aminokiselinski niz SEQ ID NO: 26.
3. Bispecifično antitijelo ili fragment za vezanje antigena prema zahtjevu 1 ili 2, gdje prva domena za vezanje antigena koja specifično veže humani CD3 sadrži domene HCDRI-HCDR2-HCDR3-LCDRI-LCDR2-LCDR3, tim redom, koje sadrže aminokiselinske nizove koji su odabrani iz grupe koja obuhvaća SEQ ID NOs: 1732-1734-1736-28-30-32, 1764-1766-1768-28-30-32, 1780-1782-1784-28-30-32, 1788-1790-1792-28-30-32, i 1868-1870-1872-28-30-32.
4. Bispecifično antitijelo ili fragment za vezanje antigena prema zahtjevu 3, gdje prva domena za vezanje antigena koja veže humani CD3 sadrži varijabilnu regiju teškog lanca (HCVR) koja sadrži aminokiselinski niz koji je odabran iz grupe koja se sastoji iz SEQ ID NOs: 1730, 1762, 1778, 1786, i 1866, i varijabilna regija lakog lanca (LCVR) koja sadrži aminokiselinski niz SEQ ID NO: 26.
5. Bispecifično antitijelo ili fragment za vezanje antigena prema zahtjevu 3, gdje prva domena za vezanje antigena sadrži domene HCDRI-HCDR2-HCDR3-LCDRI-LCDR2-LCDR3, tim redom, koji sadrže aminokiselinske sekvence SEQ ID NOs: 1732-1734-1736-28-30-32 i druga domena za vezanje antigena sadrži domene HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3, tim redom, koji sadrže aminokiselinske sekvence SEQ ID NOs: 20-22-24-28-30-32.
6. Bispecifično antitijelo ili fragment za vezanje antigena prema zahtjevu 3, gdje prva domena za vezanje antigena sadrži domene HCDRI-HCDR2-HCDR3-LCDRI-LCDR2-LCDR3, tim redom, koje sadrže aminokiselinske nizove SEQ ID NOs: 1868-1870-1872-28-30-32 i druge domene za vezanje antigena sadrže domene HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3, tim redom, koje sadrže aminokiselinske nizove SEQ ID NOs: 20-22-24-28-30-32.
7. Bispecifično antitijelo prema zahtjevu 5, gdje prva domena za vezanje antigena sadrži HCVR koja sadrži aminokiselinski niz SEQ ID NO: 1730 i LCVR koji sadrži aminokiselinski niz SEQ ID NO: 26, i gdje druga domena za vezanje antigena sadrži HCVR koji sadrži aminokiselinski niz SEQ ID NO: 18 i LCVR koji sadrži aminokiselinski niz SEQ ID NO: 26.
8. Bispecifično antitijelo prema zahtjevu 6, gdje prva domena za vezanje antigena sadrži HCVR koja sadrži aminokiselinski niz SEQ ID NO: 1866 i LCVR koji sadrži aminokiselinski niz SEQ ID NO: 26, i gdje druga domena za vezanje antigena sadrži HCVR koji sadrži aminokiselinski niz SEQ ID NO: 18 i LCVR koji sadrži aminokiselinski niz SEQ ID NO: 26.
9. Bispecifično antitijelo prema zahtjevu 7, koje sadrži prvi vezujući krak koji sadrži težak lanac koji sadrži aminokiselinski niz SEQ ID NO: 1961 i laki lanac koji sadrži aminokiselinski niz SEQ ID NO: 1960, i drugi vezujući krak koji sadrži težak lanac koji sadrži aminokiselinski niz SEQ ID NO: 1959 i laki lanac koji sadrži aminokiselinski niz SEQ ID NO: 1960.
10. Bispecifično antitijelo prema zahtjevu 8, koje sadrži prvi vezujući krak koji sadrži težak lanac koji sadrži aminokiselinski niz SEQ ID NO: 1962 i laki lanac koji sadrži aminokiselinski niz SEQ ID NO: 1960, i drugi vezujući krak koji sadrži težak lanac koji sadrži aminokiselinski niz SEQ ID NO: 1959 i laki lanac koji sadrži aminokiselinski niz SEQ ID NO: 1960.
11. Farmacetuski sastav koji sadrži bispecifično antitijelo ili fragment za vezanje antigena prema bilo kojem od zahtjeva 1-10, i farmaceutski prihvatljiv nosač ili razrjeđivač.
12. Bispecifično antitijelo ili fragment za vezanje antigena prema bilo kojem od zahtjeva 1-10, ili farmaceutski sastav prema zahtjevu 11, za upotrebu u postupku liječenja raka koji eksprimira MUC16.
13. Bispecifično antitijelo ili fragment za vezanje antigena, ili farmaceutski sastav, za upotrebu prema zahtjevu 12, pri čemu je rak odabran iz grupe koja se sastoji iz raka jajnika, raka dojke, raka pankreasa, raka nemalih ćelija pluća, intrahepatičnog holangiokarcinoma-tip koji obrazuje masu, adenokarcinoma cerviksa maternice, i adenokarcinoma želučanog trakta.
14. Bispecifično antitijelo ili fragment za vezanje antigena, ili farmaceutski sastav, za upotrebu prema zahtjevu 12, gdje je rak rak jajnika.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662399249P | 2016-09-23 | 2016-09-23 | |
US201762558711P | 2017-09-14 | 2017-09-14 | |
PCT/US2017/053113 WO2018067331A1 (en) | 2016-09-23 | 2017-09-22 | Bi specific anti-muc16-cd3 antibodies and nti-muc16 drug conjugates |
EP17784089.9A EP3515487B1 (en) | 2016-09-23 | 2017-09-22 | Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231281T1 true HRP20231281T1 (hr) | 2024-02-02 |
Family
ID=60083442
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20221202TT HRP20221202T1 (hr) | 2016-09-23 | 2017-09-22 | Anti-muc16 (mucin 16) antitijela |
HRP20231281TT HRP20231281T1 (hr) | 2016-09-23 | 2017-09-22 | Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20221202TT HRP20221202T1 (hr) | 2016-09-23 | 2017-09-22 | Anti-muc16 (mucin 16) antitijela |
Country Status (27)
Country | Link |
---|---|
US (4) | US10941208B2 (hr) |
EP (3) | EP3515946B1 (hr) |
JP (2) | JP7066691B2 (hr) |
KR (2) | KR102531251B1 (hr) |
CN (2) | CN110214026B (hr) |
AU (2) | AU2017339711B2 (hr) |
BR (2) | BR112019005697A2 (hr) |
CA (2) | CA3037738A1 (hr) |
CL (4) | CL2019000712A1 (hr) |
CO (1) | CO2019003967A2 (hr) |
DK (2) | DK3515487T5 (hr) |
ES (2) | ES2952735T3 (hr) |
FI (1) | FI3515487T3 (hr) |
HR (2) | HRP20221202T1 (hr) |
HU (2) | HUE059761T2 (hr) |
IL (2) | IL265369B2 (hr) |
LT (2) | LT3515946T (hr) |
MD (1) | MD3515487T2 (hr) |
MX (2) | MX2019003326A (hr) |
MY (1) | MY194596A (hr) |
PH (2) | PH12019500550A1 (hr) |
PL (2) | PL3515946T3 (hr) |
PT (2) | PT3515946T (hr) |
RS (2) | RS63660B1 (hr) |
SI (2) | SI3515487T1 (hr) |
WO (2) | WO2018067331A1 (hr) |
ZA (2) | ZA201901557B (hr) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
AU2016242866B2 (en) | 2015-03-30 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to FC gamma receptors |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
TWI784917B (zh) * | 2015-09-23 | 2022-11-21 | 美商再生元醫藥公司 | 最優化抗cd3雙特異性抗體及其用途 |
US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
HRP20221202T1 (hr) | 2016-09-23 | 2022-12-09 | Regeneron Pharmaceuticals, Inc. | Anti-muc16 (mucin 16) antitijela |
SG11201907208XA (en) * | 2017-02-10 | 2019-09-27 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
RU2747095C2 (ru) * | 2018-05-11 | 2021-04-26 | Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) | Мономолекулярный химерный т-клеточный рецептор к раковому антигену са125 |
CN108659131B (zh) * | 2018-05-28 | 2021-09-14 | 长春力太生物技术有限公司 | 一种抗ceacam-5的单域抗体及其应用 |
SG11202012729YA (en) | 2018-06-21 | 2021-01-28 | Regeneron Pharma | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
TW202005985A (zh) * | 2018-06-21 | 2020-02-01 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 |
TWI838389B (zh) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAx抗-CD3抗體及其用途 |
EA202190601A1 (ru) | 2018-08-23 | 2021-07-14 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FCER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FCΕR1Α И CD3, И ИХ ПРИМЕНЕНИЕ |
MA53495A (fr) | 2018-08-31 | 2021-12-08 | Regeneron Pharma | Stratégie de dosage permettant d'atténuer le syndrome de libération de cytokines pour des anticorps bispécifiques cd3/c20 |
SG11202103628PA (en) | 2018-10-31 | 2021-05-28 | Regeneron Pharma | Method and system of identifying and quantifying a protein |
BR112021009373A2 (pt) * | 2018-11-16 | 2021-08-17 | Memorial Sloan Kettering Cancer Center | anticorpos para mucina-16 e métodos de uso dos mesmos |
US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
WO2020132066A1 (en) | 2018-12-19 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof |
BR112021010457A2 (pt) * | 2018-12-19 | 2021-08-24 | Regeneron Pharmaceuticals, Inc. | Anticorpos biespecíficos anti-muc16 x anti cd28 e usos dos mesmos |
EA202192566A1 (ru) | 2019-03-22 | 2021-12-27 | Ридженерон Фармасьютикалз, Инк. | МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28 |
WO2020256721A1 (en) * | 2019-06-19 | 2020-12-24 | Synthis, Llc | Antib0dy-alk5 inhibitor conjugates and their uses |
KR20220024035A (ko) | 2019-06-21 | 2022-03-03 | 리제너론 파마슈티칼스 인코포레이티드 | Muc16 및 cd3에 결합하는 이중 특이적 항원 결합 분자와 4-1bb 공동 자극의 병용 |
CN114401988A (zh) * | 2019-07-09 | 2022-04-26 | 国家生物技术研究所公司 | 具有降低的免疫原性的抗体 |
WO2021030680A1 (en) * | 2019-08-15 | 2021-02-18 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules for cell targeting and uses thereof |
CN112969715B (zh) * | 2019-08-21 | 2022-03-18 | 和铂医药(上海)有限责任公司 | 一种抗cd47抗原结合蛋白及其应用 |
US11814428B2 (en) * | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
CN114929343A (zh) * | 2019-12-06 | 2022-08-19 | 瑞泽恩制药公司 | 用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法 |
WO2021112925A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
WO2022165171A1 (en) | 2021-01-28 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
TW202304507A (zh) * | 2021-04-02 | 2023-02-01 | 美商再生元醫藥公司 | 含有抗muc16x抗cd3雙特異性抗體之穩定調配物 |
JP2024523033A (ja) | 2021-06-17 | 2024-06-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の三重特異的結合分子 |
US20230235089A1 (en) | 2021-11-24 | 2023-07-27 | Regeneron Pharmaceuticals, Inc. | Methods for Treating Cancer with Bispecific Anti-CD3 x MUC16 Antibodies and Anti-CTLA-4 Antibodies |
KR20240130137A (ko) | 2022-01-07 | 2024-08-28 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-MUC16 x 항-CD3 항체 단독으로 또는 항-PD-1 항체와의 조합으로 재발성 난소암을 치료하는 방법 |
TW202334234A (zh) * | 2022-01-10 | 2023-09-01 | 大陸商南京維立志博生物科技有限公司 | 一種抗體及其用途 |
IL314076A (en) * | 2022-01-10 | 2024-09-01 | Regeneron Pharma | MUC16 chimeric antigen receptors |
AU2023236126A1 (en) | 2022-03-17 | 2024-09-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
WO2024051752A1 (en) * | 2022-09-06 | 2024-03-14 | I-Mab Biopharma Co., Ltd. | Multispecific constructs and uses thereof |
WO2024123698A1 (en) | 2022-12-08 | 2024-06-13 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
WO2024173830A2 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
WO2024191983A1 (en) | 2023-03-13 | 2024-09-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with bispecific anti-cd22 x anti-cd28 molecules |
CN117024596B (zh) * | 2023-08-18 | 2024-02-27 | 镜像绮点(上海)细胞技术有限公司 | 肿瘤原代细胞特异性标记与活体成像 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
AU2002254615A1 (en) * | 2001-04-17 | 2002-10-28 | The Board Of Trustees Of The University Of Arkansas | Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions |
EP1318402B1 (de) | 2001-12-04 | 2005-04-20 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 125 |
ES2535742T3 (es) | 2002-10-16 | 2015-05-14 | Purdue Pharma L.P. | Anticuerpos que se unen a CA 125/0722P asociado a células y métodos de uso de los mismos |
CA2523716C (en) | 2003-05-31 | 2014-11-25 | Micromet Ag | Human anti-human cd3 binding molecules |
AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
RS52176B (en) | 2006-06-02 | 2012-08-31 | Regeneron Pharmaceuticals Inc. | HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
PE20090245A1 (es) * | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
EP3561513A1 (en) | 2007-05-23 | 2019-10-30 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
US8187801B2 (en) * | 2008-04-24 | 2012-05-29 | Wisconsin Alumni Research Foundation | Methods and kits to detect and monitor ovarian cancer and preeclampsia |
SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
PL2326349T3 (pl) | 2008-07-21 | 2015-08-31 | Polytherics Ltd | Nowe reagenty i sposób sprzęgania cząsteczek biologicznych |
DK2975051T3 (da) | 2009-06-26 | 2021-04-26 | Regeneron Pharma | Let-at-isolere bispecifikke antistoffer med nativt immunoglobulinformat |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
WO2011018611A1 (en) | 2009-08-10 | 2011-02-17 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
RS59001B1 (sr) | 2010-02-08 | 2019-08-30 | Regeneron Pharma | Miš sa zajedničkim lakim lancem |
CA3002192C (en) * | 2010-03-26 | 2023-03-07 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
MX2012011901A (es) | 2010-04-15 | 2012-11-29 | Spirogen Sarl | Pirrolobenzodiacepinas y conjugados de las mismas. |
WO2012005982A2 (en) | 2010-07-06 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Reporter for rna polymerase ii termination |
EP2642979A4 (en) * | 2010-11-26 | 2014-09-17 | Univ Witwatersrand Jhb | PHARMACEUTICAL COMPOSITION |
US20150080559A1 (en) | 2011-05-27 | 2015-03-19 | Ambrx, Inc. | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
KR101891859B1 (ko) | 2011-10-14 | 2018-08-24 | 메디뮨 리미티드 | 피롤로벤조디아제핀 |
CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
BR112014009070B1 (pt) | 2011-10-14 | 2021-11-23 | Medimmune Limited | Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas |
EA036202B1 (ru) | 2011-10-14 | 2020-10-14 | Сиэтл Дженетикс, Инк. | Пирролбензодиазепины и конъюгаты направленного действия |
WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
IN2014CN04961A (hr) | 2011-12-05 | 2015-09-18 | Igenica Biotherapeutics Inc | |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
KR102306490B1 (ko) | 2013-03-15 | 2021-09-28 | 리제너론 파아마슈티컬스, 인크. | 생물학적 활성 분자, 그의 접합체 및 치료 용도 |
CA2921412C (en) | 2013-08-26 | 2024-05-28 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
LT3083689T (lt) * | 2013-12-17 | 2020-08-10 | Genentech, Inc. | Anti-cd3 antikūnai ir jų panaudojimo būdai |
TWI754319B (zh) * | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
RU2758113C2 (ru) * | 2015-03-17 | 2021-10-26 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Антитела к muc16 и их применение |
MX2017012380A (es) | 2015-03-27 | 2018-04-11 | Regeneron Pharma | Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. |
TWI784917B (zh) * | 2015-09-23 | 2022-11-21 | 美商再生元醫藥公司 | 最優化抗cd3雙特異性抗體及其用途 |
HRP20221202T1 (hr) | 2016-09-23 | 2022-12-09 | Regeneron Pharmaceuticals, Inc. | Anti-muc16 (mucin 16) antitijela |
-
2017
- 2017-09-22 HR HRP20221202TT patent/HRP20221202T1/hr unknown
- 2017-09-22 HU HUE17787989A patent/HUE059761T2/hu unknown
- 2017-09-22 PL PL17787989.7T patent/PL3515946T3/pl unknown
- 2017-09-22 ES ES17784089T patent/ES2952735T3/es active Active
- 2017-09-22 IL IL265369A patent/IL265369B2/en unknown
- 2017-09-22 DK DK17784089.9T patent/DK3515487T5/da active
- 2017-09-22 CN CN201780067123.9A patent/CN110214026B/zh active Active
- 2017-09-22 LT LTEPPCT/US2017/053114T patent/LT3515946T/lt unknown
- 2017-09-22 ES ES17787989T patent/ES2925563T3/es active Active
- 2017-09-22 HR HRP20231281TT patent/HRP20231281T1/hr unknown
- 2017-09-22 RS RS20220906A patent/RS63660B1/sr unknown
- 2017-09-22 BR BR112019005697A patent/BR112019005697A2/pt unknown
- 2017-09-22 PT PT177879897T patent/PT3515946T/pt unknown
- 2017-09-22 US US15/713,578 patent/US10941208B2/en active Active
- 2017-09-22 WO PCT/US2017/053113 patent/WO2018067331A1/en active Application Filing
- 2017-09-22 PL PL17784089.9T patent/PL3515487T3/pl unknown
- 2017-09-22 SI SI201731387T patent/SI3515487T1/sl unknown
- 2017-09-22 BR BR112019005670A patent/BR112019005670A2/pt unknown
- 2017-09-22 WO PCT/US2017/053114 patent/WO2018058003A1/en unknown
- 2017-09-22 CN CN201780071820.1A patent/CN110036032B/zh active Active
- 2017-09-22 EP EP17787989.7A patent/EP3515946B1/en active Active
- 2017-09-22 FI FIEP17784089.9T patent/FI3515487T3/fi active
- 2017-09-22 JP JP2019515905A patent/JP7066691B2/ja active Active
- 2017-09-22 IL IL265309A patent/IL265309B2/en unknown
- 2017-09-22 EP EP23182446.7A patent/EP4273172A3/en active Pending
- 2017-09-22 JP JP2019515904A patent/JP7066690B2/ja active Active
- 2017-09-22 US US15/713,574 patent/US10738130B2/en active Active
- 2017-09-22 HU HUE17784089A patent/HUE063020T2/hu unknown
- 2017-09-22 EP EP17784089.9A patent/EP3515487B1/en active Active
- 2017-09-22 LT LTEPPCT/US2017/053113T patent/LT3515487T/lt unknown
- 2017-09-22 AU AU2017339711A patent/AU2017339711B2/en active Active
- 2017-09-22 MX MX2019003326A patent/MX2019003326A/es unknown
- 2017-09-22 CA CA3037738A patent/CA3037738A1/en active Pending
- 2017-09-22 RS RS20230945A patent/RS64691B1/sr unknown
- 2017-09-22 DK DK17787989.7T patent/DK3515946T5/da active
- 2017-09-22 PT PT177840899T patent/PT3515487T/pt unknown
- 2017-09-22 SI SI201731189T patent/SI3515946T1/sl unknown
- 2017-09-22 AU AU2017331363A patent/AU2017331363B2/en active Active
- 2017-09-22 MD MDE20190826T patent/MD3515487T2/ro unknown
- 2017-09-22 KR KR1020197010783A patent/KR102531251B1/ko active IP Right Grant
- 2017-09-22 KR KR1020197011419A patent/KR102418667B1/ko active IP Right Grant
- 2017-09-22 CA CA3037536A patent/CA3037536A1/en active Pending
- 2017-09-22 MY MYPI2019001357A patent/MY194596A/en unknown
- 2017-09-22 MX MX2019003322A patent/MX2019003322A/es unknown
-
2019
- 2019-03-13 ZA ZA2019/01557A patent/ZA201901557B/en unknown
- 2019-03-14 PH PH12019500550A patent/PH12019500550A1/en unknown
- 2019-03-14 ZA ZA2019/01591A patent/ZA201901591B/en unknown
- 2019-03-19 PH PH12019500604A patent/PH12019500604A1/en unknown
- 2019-03-19 CL CL2019000712A patent/CL2019000712A1/es unknown
- 2019-03-20 CL CL2019000726A patent/CL2019000726A1/es unknown
- 2019-04-22 CO CONC2019/0003967A patent/CO2019003967A2/es unknown
-
2020
- 2020-06-26 US US16/913,154 patent/US11485793B2/en active Active
-
2021
- 2021-10-08 CL CL2021002645A patent/CL2021002645A1/es unknown
-
2022
- 2022-09-26 US US17/953,114 patent/US20230272111A1/en active Pending
-
2023
- 2023-09-08 CL CL2023002690A patent/CL2023002690A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20231281T1 (hr) | Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom | |
HRP20201156T1 (hr) | Zajednički laki lanci i postupci primjene | |
HRP20200070T1 (hr) | Humana antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3) i njihove primjene | |
HRP20210582T1 (hr) | Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe | |
HRP20240767T1 (hr) | Cd3 vezujuća antitijela | |
WO2016154047A3 (en) | Monoclonal antigen-binding proteins to intracellular oncogene products | |
JP2019531084A5 (hr) | ||
HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
JP2018504105A5 (hr) | ||
JP2020510422A5 (hr) | ||
IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
JP2017535257A5 (hr) | ||
RU2018106452A (ru) | Поливалетные и полиспецифичные gitr-связывающие слитые белки | |
JP2018052979A5 (hr) | ||
HRP20211710T1 (hr) | Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat | |
JP2016521692A5 (hr) | ||
EA201391159A1 (ru) | Hla-рестриктированные пептидоспецифические антигенсвязывающие белки | |
HRP20200034T1 (hr) | Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka | |
FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
JP2013517487A5 (hr) | ||
JP2011157397A5 (hr) | ||
HRP20221088T1 (hr) | Protutijela i postupci uporabe | |
RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
PE20071055A1 (es) | Anticuerpos anti mn |